<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Big Tobacco Isn’t Up in Smoke Just Yet — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Big Tobacco Isn’t Up in Smoke Just Yet</h2>
    <div class="badge">2025-09-15T10:30:00+00:00</div>
    <ul>
      <li>in its most recent quarter; its share price is up 27% year-to-date.</li>
<li>Meanwhile, Altria reported 26% year-over-year growth in shipments of its Zyn competitor on!</li>
<li>- Zyn drove shipments of oral smoke-free products above 200 million cans in the Americas in PMI’s most recent quarter, up 32% year-over-year; the company’s stock is up more than 37% year-to-date as of Friday.</li>
<li>A Credit Suisse study, also cited by the WSJ, found that the industry outperformed all other sectors in the US between 1900 and 2015.</li>
<li>That’s because way back in the late 1990s, major US tobacco companies agreed to pay 52 US municipalities and states $206 billion over the next 25 years (in exchange, those jurisdictions gave up their right to legal claim</li>
<li>Big Tobacco has also largely evaded scrutiny from the Make America Healthy Again movement, and its product tends to do well amid periods of economic uncertainty anyhow: - So far this year, a basket of six global tobacco</li>
<li>READ ALSO: Buffett’s Berkshire’s Short Term Interest Rate Path Differs From Megarich Peers and Alphabet Rides The AI Wave Over The $3 Trillion Mark Zyn Vogue Historically, the FDA takes a long time to grant its stamp of</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Big Tobacco Isn’t Up in Smoke Just Yet\n• in its most recent quarter; its share price is up 27% year-to-date.\n• Meanwhile, Altria reported 26% year-over-year growth in shipments of its Zyn competitor on!\n• - Zyn drove shipments of oral smoke-free products above 200 million cans in the Americas in PMI’s most recent quarter, up 32% year-over-year; the company’s stock is up more than 37% year-to-date as of Friday.\n• A Credit Suisse study, also cited by the WSJ, found that the industry outperformed all other sectors in the US between 1900 and 2015.\n• That’s because way back in the late 1990s, major US tobacco companies agreed to pay 52 US municipalities and states $206 billion over the next 25 years (in exchange, those jurisdictions gave up their right to legal claim\n• Big Tobacco has also largely evaded scrutiny from the Make America Healthy Again movement, and its product tends to do well amid periods of economic uncertainty anyhow: - So far this year, a basket of six global tobacco\n• READ ALSO: Buffett’s Berkshire’s Short Term Interest Rate Path Differs From Megarich Peers and Alphabet Rides The AI Wave Over The $3 Trillion Mark Zyn Vogue Historically, the FDA takes a long time to grant its stamp of" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/4e374237-ecd0-3f78-9960-129a6d55e1c1/big-tobacco-isn%E2%80%99t-up-in-smoke.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>